Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group - PubMed (original) (raw)

Meta-Analysis

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

No authors listed. BMJ. 1991.

Abstract

Objectives: To consider the role of platinum and the relative merits of single agent and combination chemotherapy in the treatment of advanced ovarian cancer.

Design: Formal quantitative overview using updated individual patient data from all available randomised trials (published and unpublished).

Subjects: 8139 patients (6408 deaths) included in 45 different trials.

Results: No firm conclusions could be reached. Nevertheless, the results suggest that in terms of survival immediate platinum based treatment was better than non-platinum regimens (overall relative risk 0.93; 95% confidence interval 0.83 to 1.05); platinum in combination was better than single agent platinum when used in the same dose (overall relative risk 0.85; 0.72 to 1.00); and cisplatin and carboplatin were equally effective (overall relative risk 1.05; 0.94 to 1.18).

Conclusions: In the past, randomised clinical trials of chemotherapy in advanced ovarian cancer have been much too small to detect the degree of benefit which this overview suggests is realistic for currently available chemotherapeutic regimens. Hence a new trial comparing cisplatin, doxorubicin, and cyclophosphamide (CAP) with carboplatin has been launched and plans to accrue 2000 patients.

PubMed Disclaimer

Comment in

• Chemotherapy in advanced ovarian cancer.
  Izard M. Izard M. BMJ. 1992 Jan 11;304(6819):119. doi: 10.1136/bmj.304.6819.119. BMJ. 1992. PMID: 1531310 Free PMC article. No abstract available.
• Chemotherapy in advanced ovarian cancer.
  Cruickshank DJ. Cruickshank DJ. BMJ. 1991 Nov 16;303(6812):1269. doi: 10.1136/bmj.303.6812.1269-a. BMJ. 1991. PMID: 1747658 Free PMC article. No abstract available.

Similar articles

• Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
  Williams CJ, Stewart L, Parmar M, Guthrie D. Williams CJ, et al. Semin Oncol. 1992 Feb;19(1 Suppl 2):120-8. Semin Oncol. 1992. PMID: 1411623
• Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
  Stewart L; Advanced Ovarian Cancer Trialists Group. Stewart L, et al. Cochrane Database Syst Rev. 2000;(2):CD001418. doi: 10.1002/14651858.CD001418. Cochrane Database Syst Rev. 2000. PMID: 10796788 Review.
• Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
  Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Yeap BY, et al. Aabo K, et al. Br J Cancer. 1998 Dec;78(11):1479-87. doi: 10.1038/bjc.1998.710. Br J Cancer. 1998. PMID: 9836481 Free PMC article.
• The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn?
  Stewart LA, Parmar MK. Stewart LA, et al. Bull Cancer. 1993 Feb;80(2):146-51. Bull Cancer. 1993. PMID: 8173166 Clinical Trial.
• Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
  Gadducci A, Brunetti I, Cosio S, Giannessi PG, Genazzani AR, Conte P. Gadducci A, et al. Anticancer Res. 1997 Nov-Dec;17(6D):4703-8. Anticancer Res. 1997. PMID: 9494592 Review.

Cited by

• How individual participant data meta-analyses have influenced trial design, conduct, and analysis.
  Tierney JF, Pignon JP, Gueffyier F, Clarke M, Askie L, Vale CL, Burdett S; Cochrane IPD Meta-analysis Methods Group. Tierney JF, et al. J Clin Epidemiol. 2015 Nov;68(11):1325-35. doi: 10.1016/j.jclinepi.2015.05.024. Epub 2015 Jun 3. J Clin Epidemiol. 2015. PMID: 26186982 Free PMC article.
• Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
  Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA. Olawaiye AB, et al. Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Gynecol Oncol. 2018. PMID: 30135020 Free PMC article. Clinical Trial.
• New developments and approaches in the platinum arena.
  Judson I, Kelland LR. Judson I, et al. Drugs. 2000;59 Suppl 4:29-36; discussion 37-8. doi: 10.2165/00003495-200059004-00004. Drugs. 2000. PMID: 10864228 Review.
• The role of platinum dose intensity in the management of ovarian cancer.
  Markman M. Markman M. J Cancer Res Clin Oncol. 1993;119(9):511-2. doi: 10.1007/BF01686459. J Cancer Res Clin Oncol. 1993. PMID: 8325902 No abstract available.
• Clinical pharmacokinetics and dose optimisation of carboplatin.
  Duffull SB, Robinson BA. Duffull SB, et al. Clin Pharmacokinet. 1997 Sep;33(3):161-83. doi: 10.2165/00003088-199733030-00002. Clin Pharmacokinet. 1997. PMID: 9314610 Review.

References

1. 1. J Clin Oncol. 1989 Nov;7(11):1748-56 - PubMed
2. 1. Gan To Kagaku Ryoho. 1988 Aug;15(8):2297-304 - PubMed
3. 1. J Natl Cancer Inst. 1989 Oct 4;81(19):1500-4 - PubMed
4. 1. J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71 - PubMed
5. 1. Acta Oncol. 1989;28(1):57-60 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal